235 related articles for article (PubMed ID: 28152531)
1. Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE).
Roquin G; Baudin E; Lombard-Bohas C; Cadiot G; Dominguez S; Guimbaud R; Niccoli P; Legoux JL; Mitry E; Rohmer V; Ruszniewski P; Walter T; Ducreux M; Couvelard A; Scoazec JY; Ramond-Roquin A; Caroli-Bosc FX; Hentic O
Neuroendocrinology; 2018; 106(1):38-46. PubMed ID: 28152531
[TBL] [Abstract][Full Text] [Related]
2. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.
Heetfeld M; Chougnet CN; Olsen IH; Rinke A; Borbath I; Crespo G; Barriuso J; Pavel M; O'Toole D; Walter T;
Endocr Relat Cancer; 2015 Aug; 22(4):657-64. PubMed ID: 26113608
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?
Lamarca A; Elliott E; Barriuso J; Backen A; McNamara MG; Hubner R; Valle JW
Cancer Treat Rev; 2016 Mar; 44():26-41. PubMed ID: 26855376
[TBL] [Abstract][Full Text] [Related]
4. Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors.
Rogers JE; Lam M; Halperin DM; Dagohoy CG; Yao JC; Dasari A
Neuroendocrinology; 2022; 112(1):34-42. PubMed ID: 33434908
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.
de Mestier L; Walter T; Brixi H; Evrard C; Legoux JL; de Boissieu P; Hentic O; Cros J; Hammel P; Tougeron D; Lombard-Bohas C; Rebours V; Ruszniewski P; Cadiot G
Neuroendocrinology; 2019; 108(4):343-353. PubMed ID: 30759445
[TBL] [Abstract][Full Text] [Related]
6. Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.
Girot P; Dumars C; Mosnier JF; Muzellec L; Senellart H; Foubert F; Caroli-Bosc FX; Cauchin E; Regenet N; Matysiak-Budnik T; Touchefeu Y
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):826-830. PubMed ID: 28328619
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)--a phase II non-randomised trial.
Ducreux M; Dahan L; Smith D; O'Toole D; Lepère C; Dromain C; Vilgrain V; Baudin E; Lombard-Bohas C; Scoazec JY; Seitz JF; Bitoun L; Koné S; Mitry E
Eur J Cancer; 2014 Dec; 50(18):3098-106. PubMed ID: 25454412
[TBL] [Abstract][Full Text] [Related]
8. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
[TBL] [Abstract][Full Text] [Related]
9. Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors.
Mueller D; Krug S; Majumder M; Rinke A; Gress TM
BMC Cancer; 2016 Aug; 16():645. PubMed ID: 27538897
[TBL] [Abstract][Full Text] [Related]
10. The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors.
Krug S; Gress TM; Michl P; Rinke A
Digestion; 2017; 96(2):67-75. PubMed ID: 28728148
[TBL] [Abstract][Full Text] [Related]
11. Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less.
Özaslan E; Karaca H; Koca S; Sevinç A; Hacioğlu B; Özkan M; Özçelik M; Duran AO; Hacibekiroğlu İ; Yildiz Y; Tanriverdi Ö; Menekşe S; Aksoy A; Bozkurt O; Urvay S; Uysal M; Demir H; Çiltaş A; Dane F
Anticancer Drugs; 2017 Feb; 28(2):222-229. PubMed ID: 27768606
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of endoscopic ultrasonography-guided fine needle aspiration for pancreatic neuroendocrine tumor grading.
Sugimoto M; Takagi T; Hikichi T; Suzuki R; Watanabe K; Nakamura J; Kikuchi H; Konno N; Waragai Y; Asama H; Takasumi M; Watanabe H; Obara K; Ohira H
World J Gastroenterol; 2015 Jul; 21(26):8118-24. PubMed ID: 26185384
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine-Temozolomide in Advanced Grade 2 and Grade 3 Neuroendocrine Neoplasms: Benefits of Chemotherapy in Neuroendocrine Neoplasms with Significant 18FDG Uptake.
Ostwal V; Basu S; Bhargava P; Shah M; Parghane RV; Srinivas S; Chaudhari V; Bhandare MS; Shrikhande SV; Ramaswamy A
Neuroendocrinology; 2021; 111(10):998-1004. PubMed ID: 33017827
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors.
Spada F; Antonuzzo L; Marconcini R; Radice D; Antonuzzo A; Ricci S; Di Costanzo F; Fontana A; Gelsomino F; Luppi G; Nobili E; Galdy S; Cella CA; Sonzogni A; Pisa E; Barberis M; Fazio N
Neuroendocrinology; 2016; 103(6):806-14. PubMed ID: 26789262
[TBL] [Abstract][Full Text] [Related]
15. The value of the Ki-67 proliferation marker as a prognostic factor in gastroenteropancreatic neuroendocrine tumours.
Foltyn W; Zajęcki W; Marek B; Kajdaniuk D; Siemińska L; Zemczak A; Kos-Kudła B
Endokrynol Pol; 2012; 63(5):362-6. PubMed ID: 23115069
[TBL] [Abstract][Full Text] [Related]
16. Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort.
Lithgow K; Venkataraman H; Hughes S; Shah H; Kemp-Blake J; Vickrage S; Smith S; Humphries S; Elshafie M; Taniere P; Diaz-Cano S; Dasari BVM; Almond M; Ford S; Ayuk J; Shetty S; Shah T; Geh I
Sci Rep; 2021 Sep; 11(1):17947. PubMed ID: 34504148
[TBL] [Abstract][Full Text] [Related]
17. Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours.
Childs A; Kirkwood A; Edeline J; Luong TV; Watkins J; Lamarca A; Alrifai D; Nsiah-Sarbeng P; Gillmore R; Mayer A; Thirlwell C; Sarker D; Valle JW; Meyer T
Endocr Relat Cancer; 2016 Jul; 23(7):563-70. PubMed ID: 27412968
[TBL] [Abstract][Full Text] [Related]
18. MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.
Cros J; Hentic O; Rebours V; Zappa M; Gille N; Theou-Anton N; Vernerey D; Maire F; Lévy P; Bedossa P; Paradis V; Hammel P; Ruszniewski P; Couvelard A
Endocr Relat Cancer; 2016 Aug; 23(8):625-33. PubMed ID: 27353036
[TBL] [Abstract][Full Text] [Related]
19. The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.
Ramirez RA; Beyer DT; Chauhan A; Boudreaux JP; Wang YZ; Woltering EA
Oncologist; 2016 Jun; 21(6):671-5. PubMed ID: 27226359
[TBL] [Abstract][Full Text] [Related]
20. Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours.
Dilz LM; Denecke T; Steffen IG; Prasad V; von Weikersthal LF; Pape UF; Wiedenmann B; Pavel M
Eur J Cancer; 2015 Jul; 51(10):1253-62. PubMed ID: 25935542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
